Accordingly, an “orchestrated” strategy to achieve immunogenic cell death has been proposed by researchers at ImmunityBio: first, low-dose metronomic chemotherapy and stereotactic body radiotherapy (SBRT) induce tumor cell death thereby releasing TAAs; second, adenoviral and yeast vector-based cancer vaccines evoke anti-tumor T-cell immunity to the released TAAs; third, T-cell activity is further enhanced through the infusion of off-the-shelf, high-affinity natural killer (haNK) cells along with IL-15 superagonist N-803, and checkpoint inhibition. Here, IL15 is linked to neoplasm.